Indeed, relating to the well-known ability of cancer cells to use inhibitory checkpoints to induce T cells apoptosis or anergy, Vδ2 T cells results not to be affected by this immunosuppressive mechanisms by the very low expression of PD-1 compared to conventional αβ CD8 and CD4 T cells; a recent paper have demonstrated that upon 4 days of in vitro stimulation by Zoledronate and IL-2, Vδ2 T cells increase the expression of PD-1 but very rapidly decrease nearly to baseline (86) as well as TIGIT that is another negative checkpoint receptor (Hayday, unpublished results). This evidence concerns the gene CD4 and cancer.